

Unaudited Financial Statements for the Year Ended 30 June 2022

for

Forward Clinical Limited

Davis Grant Limited
Chartered Certified Accountants
Treviot House
186-192 High Road
Ilford
Essex
IG1 1LR

**Contents of the Financial Statements
for the Year Ended 30 June 2022**

	Page
Balance Sheet	1
Notes to the Financial Statements	3

Forward Clinical Limited (Registered number: 10420044)

Balance Sheet
30 June 2022

	Notes	2022 £	£	2021 £	£
FIXED ASSETS					
Intangible assets	4		2,056		2,343
Tangible assets	5		<u>12,770</u>		<u>32,909</u>
			14,826		35,252
CURRENT ASSETS					
Debtors	6	175,502		135,795	
Cash at bank		<u>26,634</u>		<u>525,000</u>	
		202,136		660,795	
CREDITORS					
Amounts falling due within one year	7	<u>859,928</u>		<u>711,466</u>	
NET CURRENT LIABILITIES			<u>(657,792)</u>		<u>(50,671)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			(642,966)		(15,419)
CREDITORS					
Amounts falling due after more than one year	8		<u>5,116,037</u>		<u>4,111,594</u>
NET LIABILITIES			<u>(5,759,003)</u>		<u>(4,127,013)</u>
CAPITAL AND RESERVES					
Called up share capital			3		3
Share premium			3,508,335		3,508,335
Other reserves			1,103,789		754,408
Retained earnings			<u>(10,371,130)</u>		<u>(8,389,759)</u>
			<u>(5,759,003)</u>		<u>(4,127,013)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The notes form part of these financial statements

Balance Sheet - continued
30 June 2022

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 21 September 2022 and were signed on its behalf by:

P Mundy - Director

**Notes to the Financial Statements
for the Year Ended 30 June 2022**

1. STATUTORY INFORMATION

Forward Clinical Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 10420044
Registered office: 300 St. John Street
London
EC1V 4PA

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of ten years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Fixtures and fittings	- 33% on cost
Computer equipment	- 33% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

**Notes to the Financial Statements - continued
for the Year Ended 30 June 2022**

2. ACCOUNTING POLICIES - continued

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Share based payments

The grant date fair value of share-based payments awards granted to employees is recognised as an employee expense, with a corresponding increase in equity, over the period in which the employees become unconditionally entitled to the awards. The fair value of the awards granted is measured using an option valuation model, taking into account the terms and conditions upon which the awards were granted. The amount recognised as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognised as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes.

Going concern

Whilst the directors note that the company is loss-making, the company is in its fifth year of trading and as such is in its development and growth phase. The directors have assessed the balance sheet and likely future cash flows at the date of approving these financial statements. The directors have concluded that the company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements given the level of cash held and the prospect of further funding and investment.

Accordingly, the company continues to adopt the going concern basis in preparing the financial statements.

Convertible loan notes

The component parts of compound instruments issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. On initial recognition, the financial liability component is recorded at its fair value. At the date of issue, in the case of a convertible bond denominated in the functional currency of the issuer that may be converted into a fixed number of equity shares, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in the equity reserve within equity and is not subsequently remeasured.

Transaction costs are apportioned between the liability and equity components of the convertible instrument based on their relative fair values at the date of issue. The portion relating to the equity component is charged directly against equity.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 19 (2021 - 28) .

Notes to the Financial Statements - continued
for the Year Ended 30 June 2022

4. INTANGIBLE FIXED ASSETS

Other
intangible
assets
£**COST**At 1 July 2021
and 30 June 20222,869**AMORTISATION**

At 1 July 2021

526

Charge for year

287

At 30 June 2022

813**NET BOOK VALUE**

At 30 June 2022

2,056

At 30 June 2021

2,343

5. TANGIBLE FIXED ASSETS

Plant and
machinery
etc
£**COST**

At 1 July 2021

88,202

Additions

2,521

At 30 June 2022

90,723**DEPRECIATION**

At 1 July 2021

55,293

Charge for year

22,660

At 30 June 2022

77,953**NET BOOK VALUE**

At 30 June 2022

12,770

At 30 June 2021

32,909

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2022

2021

£

£

Trade debtors

115,71119,216

Other debtors

59,791116,579175,502135,795

Notes to the Financial Statements - continued
for the Year Ended 30 June 2022

7. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2022	2021
	£	£
Bank loans and overdrafts	12,000	9,167
Trade creditors	158,730	203,460
Taxation and social security	233,652	270,748
Other creditors	455,546	228,091
	<u>859,928</u>	<u>711,466</u>

8. **CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	2022	2021
	£	£
Bank loans	28,104	40,834
Other creditors	5,087,933	4,070,760
	<u>5,116,037</u>	<u>4,111,594</u>

Amounts falling due in more than five years:

Repayable by instalments		
Bank loans more 5 yr by instal	-	834

9. **OTHER FINANCIAL COMMITMENTS**

Total future minimum lease payments under non-cancellable operating leases are £74,814 (2021: £120,814).

10. **DIRECTORS' ADVANCES, CREDITS AND GUARANTEES**

The following advances and credits to directors subsisted during the years ended 30 June 2022 and 30 June 2021:

Director 1		2022	2021
	£		
Amounts Advanced		120,083	94,361
Amounts Repaid		(38,001)	(51,000)
Director 2		2022	2021
	£		
Amounts Advanced		5,000	-
Amounts Repaid		-	-

The loans to directors are repayable on demand. Interest is charged at the rate set by HMRC.

Notes to the Financial Statements - continued
for the Year Ended 30 June 2022

11. SHARE-BASED PAYMENT TRANSACTIONS

The company operates an equity settled Enterprise Management Incentive (EMI) Share Option Scheme. The options are granted with a fixed exercise price determined at the grant of the option. The options vest over a period of up to 4 years following the date of the grant. The options are exercisable until up to the 10th anniversary from the date of grant. Employees are not entitled to dividends until the shares are exercised. Vesting of options is subject to continued employment with the company.

The company has the following number of ordinary & non voting shares issuable under share options.

Scheme	Date of Grant	Number of Shares Under Options	Exercise Price
Enterprise Management Scheme	03/08/2017-04/10/2021	8,485	£0.00001 - £0.80
Total		8,485	
Name of shares	EMI Scheme		
Brought forward		6,985	
Granted in the year		4,314	
Exercised in the year		nil	
Lapsed in the year		2,814	
Carried forward		8,485	
Exercisable in the year		891	

The fair value of the options granted have been calculated using the Black Scholes model. The total charge for the period was determined to be immaterial.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.